FAS and metabolic dysfunction-associated steatotic liver disease: Recombinant IL-22 inhibited the hepatic expression of several lipogenic genes, including that of fatty acid synthase (FAS) in HepG2 cell line and HFD-induced NAFLD mice, which led to the reduction of hepatic steatosis [79].